Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1006 ECP Scribe EMBARGO 7AM PT TUES
BioCentury & Getty Images

Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Doudna’s latest CRISPR play uses engineered enzymes to improve therapeutic properties

Doudna’s latest CRISPR play uses engineered enzymes to improve therapeutic properties.

Oct 6, 2020 | 10:26 PM GMT

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.

Scribe Therapeutics

Read the full 762 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE